Clinical Trial Update: Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients [Phase 2]

View source ↗

Summary

Phase 2 clinical trial assessing the immune response to the pneumococcal polysaccharide vaccine in patients with asplenia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asplenia

Drugs mentioned

• Pneumococcal polysaccharide vaccine (PPSV23) (Pneumococcal polysaccharide vaccine)

Snippet

Sponsor: University of California, Davis | Conditions: Asplenia | Phase 2 | Status: RECRUITING